Drug intelligence / Profile preview

lactobacillus rhamnosus postbiotic

Development stage
Preclinical
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

**Lactobacillus rhamnosus postbiotic** refers to soluble factors (metabolites, proteins, secreted molecules) produced by the fermentation or breakdown of *Lactobacillus rhamnosus* (often strain GG) after the bacterial cells are removed or inactivated. Unlike probiotics (live bacteria), postbiotics contain no viable organisms but can exert health benefits via immune modulation, anti-inflammatory effects, maintenance of epithelial integrity, and protection of the intestinal barrier. Mechanistically, these effects are primarily attributed to secreted proteins (such as p40, p75, HM0539 hydrolase), metabolites, and cell wall components, which reduce pro-inflammatory signaling (notably NF-κB and mTOR), promote epithelial survival, and enhance anti-inflammatory cytokine production (e.g., IL-10)[2][3][5]. Studied mostly in gastrointestinal and inflammatory conditions, postbiotics may offer safer alternatives to live bacteria, especially in immune-compromised patients.

Other names
lactobacillus rhamnosus GG postbioticLGG postbioticHM0539 hydrolase (for specific postbiotic protein derivative)
02

Targets

TJP1 (Tight junction protein 1 (ZO-1))IL10 (Interleukin-10)RELA (Nuclear Factor Kappa B Subunit p65)

Beyond the preview

Go deeper on lactobacillus rhamnosus postbiotic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus rhamnosus postbiotic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call